The leading manufacturer of drugs and immunisations for animals and pets worldwide is an American pharmaceutical business by the name of Zoetis Inc. The company was a division of Pfizer, the biggest pharmaceutical corporation in the world; however, when Pfizer spun off its 83% ownership stake in the company, the company is now totally independent. The business sells its goods in more than 100 countries and markets them directly in around 45 of those nations. Operations outside of the United States produced 50% of the overall revenue. In June 2013, S&P Dow Jones Indices announced that First Horizon National Corporation will be replaced by Zoetis in the S&P 500 stock market index. This was made public at the same time as the spinoff.

In November 2015, the company announced that it will spend $765 million to acquire Pharmaq, a company that develops ailments and treatments for aquaculture. In 2017, Zoetis acquired Irish-based Nexvet, a company with a biologics-focused technology and product candidate pipeline.

In May 2018, the company announced its intention to acquire Abaxis for $1.9 billion in cash.

The company’s presence in New Zealand, the US, Canada, and the UK grew after Zoetis announced in August 2021 that it would buy Jurox.

In order to broaden its selection of specialized animal health solutions, Zoetis acquired privately held genetics firm Basepaws in June 2022.

Prices

 On May 4th, Zoetis (NYSE:ZTS – Get Free Report) released its most recent quarterly results report. The company’s $1.31 quarterly profits per share was $0.04 more than the $1.27 average projection. The company’s revenue for the quarter was $2 billion as opposed to the average projection of $2.02 billion. Net margin for Zoetis was 25.59%, while return on equity was 50.26%. The revenue for Zoetis grew by.7% as compared to the same quarter the prior year. For the same quarter a year ago, the company’s earnings per share were $1.32.

ZTS has been the subject of several further research projects. They gave the company a “buy” recommendation. In a research note published on Tuesday, April 11th, Bank Of America (Bofa) raised their “buy” rating and price target on Zoetis from $180.00 to $200.00. Last but not least, Piper Sandler cut their price target on Zoetis from $220.00 to $210.00 in a research report released on Monday, May 8. MarketBeat.com reports that the company now has a consensus rating of “Buy” with an average target price of $220.50. Buy ratings have been given to the stock by seven analysts.

Highlights

• The current mood is positive.
• 30 days ago, there were 17 green days, or 57%.

Risk Analysis

• Trading at 2.9% above our expectation for the next five days,
• Value above has decreased 1.7% in the last year.
• The Fear & Greed Index shows fear.

Analysis

On Thursday, Zoetis shares began trading at $172.00. The debt-to-equity ratio for the firm is 1.46, the quick ratio is 1.94, and the current ratio is 3.27. The stock’s fifty-day and two-hundred-day moving averages are $171.96 and $167.50, respectively. The firm is valued at $79.48 billion, with a price-to-earnings ratio of 38.83, a PEG ratio of 2.75, a beta of 0.77, and a market capitalization of that amount. The 52-week low for Zoetis is $124.15, and the 52-week high is $187.82.

On Tuesday, April 18th, EVP Roxanne Lagano completed a transaction in which she sold 4,338 shares of Zoetis stock. The stock was sold for a total of $763,227.72 at an average price of $175.94 per share. The executive vice president now owns 26,357 company shares worth $4,637,250.58 after the purchase. The Securities & Exchange Commission received notice of the transaction via a legal filing, which is accessible via this website. Insiders are the owners of 0.12% of the stock.

Dividend announced by Zoetis

A quarterly dividend was also just declared by the business and will be paid on Friday, September 1. A $0.375 dividend will be paid to shareholders of record on Friday, July 21. On an annualized basis, this equals a $1.50 dividend with a yield of 0.87%. This dividend’s ex-dividend date is July 20th, a Thursday. The current payout ratio for Zoetis is 33.86%.

Company Profile for Zoetis

Animal health medications, vaccinations, and diagnostic items are discovered, developed, produced, and sold by Zoetis Inc. both domestically and abroad. It largely commercializes items from a variety of species, including companion animals like dogs, cats, and horses, as well as livestock like cattle, swine, poultry, fish, and sheep.

Daily Chart 

The Moving Averages Convergence Divergence (MACD) indicator for Zoetis (ZTS) is at -0.04, indicating that Zoetis is a Sell.

With a share price of $171 and a 20-Day Exponential Moving Average of 169.75, Zoetis (ZTS) is a Buy.

With a 50-day exponential moving average of 170.30 and a share price of $171, Zoetis (ZTS) is a Buy.

Weekly Chart

The Moving Averages Convergence Divergence (MACD) indicator for Zoetis (ZTS) is 1.97, indicating that it is a Buy.

With a share price of $171 and a 20-Day Exponential Moving Average of 169.42, Zoetis (ZTS) is a Buy.

With a 50-day exponential moving average of 168.14 and a share price of $171, Zoetis (ZTS) is a Buy.

Trading

The Relative Strength Index (RSI) for Zoetis (ZTS) is 52.66, producing a Neutral signal.

The Trend Strength Indicator (ADX) for Zoetis (ZTS) is 16.20, indicating a Buy signal.

The Commodity Channel Index (CCI) for Zoetis (ZTS) is -1.77, producing a Neutral signal.

The price rate of change (ROC) for Zoetis (ZTS) is 3.48, generating a buy signal.

Prediction

By July 19, 2023, the value of Zoetis shares will decrease by -2.82% and reach $ 166.22 per share, based on our most recent ZTS stock projection. Our technical indicators indicate that the market is now bullish, despite the Fear & Greed Index reading of 39 (Fear). With 1.63% price volatility over the previous 30 days, ZTS stock experienced 17/30 (or 57%) green days. Given that ZTS stock is now trading 2.90% over our projection, it is not a good time to purchase it based on our Zoetis stock forecast.

With 22 technical analysis indicators signaling bullish signals and 4 technical analysis indicators signaling bearish signals, as of July 14, 2023 at 14:15, the general mood towards the ZTS stock outlook is positive.

2025 Zoetis Stock Prediction

The current value of the Zoetis stock forecast for 2025 is $238.49, based on the assumption that the company’s shares would increase at the same average annual rate as they did during the previous ten years. The price of ZTS stock would increase by 39.43% as a result.

2030 Zoetis Stock Prediction

If the Zoetis stock continues to rise at its current 10-year average pace, it will reach $547.48 in 2030. If our Zoetis stock forecast for 2030 comes true, the price of ZTS stock will increase by 220.07% from the present.